Dr. Reddy's Laboratories Limited
RDY
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $10.0B
$11.97
▼ -0.50%
P/E
200.58
Mkt Cap
$10.0B
52-Wk Range
$11.36–$15.67
52-Week Range
$11.36 - $15.67
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 16.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.3).
- Premium valuation to sector peers
Growth
Strong growth ahead
Value
Premium valuation to sector peers
Momentum
Weak
-9.5% over 3m
Quality
Strong
Strong fundamentals
Dividend
Modest
0.70% yield
Smart-money signal
Who's buying RDY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 23, 2026
JUL 21, 2026
Reported EPS of $0.06 vs $0.09 consensus (-34.6% surprise). Revenue of $835.7M vs $850.6M expected (-1.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-34.6%
Revenue trend · last 8Q
—
+16%
+20%
+11%
+10%
+4%
-10%
+8992%
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
Q3 26
Q4 26
Q1 27
$8.8M
$9.1M
$9.3M
$9.3M
$9.6M
$9.5M
$8.3M
$848.4M
Margins · last 8Q
Profit
5.5%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How RDY stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.